Leading cancer researchers update and review the mechanisms of
action and the therapeutic selectivity and efficacy of 5-FU with
and without leucovorin and its prodrugs in the treatment of
colorectal cancer. Among the combination agents considered are
UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of
thymidylate synthase inhibitors. The authors discuss the potential
advantages and disadvantages of these varied drugs and their mode
of administration. Based on historical results with these agents
when used alone, they also present a rationale for their results
when used in combination with other agents.
General
| Imprint: |
HumanaPress
|
| Country of origin: |
United States |
| Series: |
Cancer Drug Discovery and Development |
| Release date: |
November 2010 |
| First published: |
2003 |
| Editors: |
Youcef M. Rustum
|
| Dimensions: |
254 x 178 x 18mm (L x W x T) |
| Format: |
Paperback
|
| Pages: |
326 |
| Edition: |
Softcover reprint of hardcover 1st ed. 2003 |
| ISBN-13: |
978-1-61737-274-2 |
| Categories: |
Books >
Medicine >
Clinical & internal medicine >
Diseases & disorders >
Oncology >
General
|
| LSN: |
1-61737-274-9 |
| Barcode: |
9781617372742 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
